



The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee April 2022 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Adalimumab	Humira	Musculoskeletal and joint disease	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
2	Adalimumab	Idacio	Musculoskeletal and joint disease	Rejected	Alternative(s) available in HADF with comparable benefits
3	Adalimumab	Hyrimoz	Musculoskeletal and joint disease	Approved	
4	Alpelisib	Piqray	Malignant disease and immunosuppression	Rejected	Insufficient comparative studies versus existing treatment
5	Atezolizumab / Bevacizumab	Tecentriq / Avastin	Malignant disease and immunosuppression	Approved	
6	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Approved	
7	Brentuximab Vedotin	Adcetris	Malignant disease and immunosuppression	Approved	
8	Brolucizumab	Beovu	Eye	Rejected	Alternative(s) available in HADF with comparable benefits
9	Canakinumab	Ilaris	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient Alternative(s) available in HADF with comparable benefits
10	Dapagliflozin	Forxiga	Endocrine system	Approved	
11	Daratumumab	Darzalex	Malignant disease and immunosuppression	Pending	Pending further information
12	Durvalumab	Imfinzi	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
13	Empagliflozin	Jardiance	Endocrine system	Approved	
14	Enzalutamide	Xtandi	Malignant disease and immunosuppression	Pending	Pending further information
15	Etanercept	Enbrel	Musculoskeletal and joint disease	Approved	
16	Inclisiran	Leqvio	Cardiovascular system	Approved	
17	Lanadelumab	Takhzyro	Respiratory system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
18	Lemborexant	Dayvigo	Central nervous system	Rejected	Insufficient evidence of long-term safety

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
19	Lenvatinib / Pembrolizumab	Lenvima / Keytruda	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
20	Lorlatinib	Lorviqua	Malignant disease and immunosuppression	Approved	
21	Macitentan	Opsumit	Cardiovascular system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
22	Ofatumumab	Kesimpta	Malignant disease and immunosuppression	Pending	Pending further information
23	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
24	Regorafenib	Stivarga	Malignant disease and immunosuppression	Approved	
25	Risdiplam	Evrysdi	Musculoskeletal and joint disease	Pending	Pending further information
26	Siltuximab	Sylvant	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
27	Venetoclax	Venclexta	Malignant disease and immunosuppression	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.